In
the annual slew of evaluations of year-long stock performances, Galena
Biopharma emerged as a strong biotech stock performer, posting triple-digit
gains in the near-year-end period from 2011 to 2012 as well as 2012 to 2013.
Articles published in outlets such as Seeking Alpha, Gaining Green, and
iStreetWire noted that the biopharmaceutical company has generated some of the
strongest returns in biotech stocks this year and last, with over 150% gains in
December 2012 to December 2013 and over 300% gains in December 2011 to December
2012.
In
particular, the iStreetWire article highlighted that Galena Biopharma made
substantial gains with its development of several biopharmaceutical
industry-bending cancer treatments. Many notable hedge funds added shares of
the biopharmaceutical company to their portfolio holdings, a demonstration of
the buzz the company has been receiving, as well as the prospective investment
potential it may hold.
The
company is currently making strong progress in its bring-to-market efforts of
NeuVax™, a cancer immunotherapy that targets HER-2 presenting cells, a
well-established point for cancer treatment. HER-2 is a tumor-associated
antigen that is observable in different expressions of many types of human
cancer cells. This immunotherapeutic solution harnesses the power of the immune
system to target and destroy cancer cells that process HER-2 as well as inhibit
any future appearances of these cells. This prospective medical breakthrough is
currently in Phase III testing. If Galena Biopharma posts more positive
developments in the immunotherapy’s clinical testing, its shares could generate
further astronomic investor returns in 2014.
Earlier
in 2013, Galena Biopharma acquired Abstral®, a sublingual tablet that enables
patient management of breakthrough cancer pain, which is typically associated
with patients who are receiving chronic, long-acting opioid pain management and
nonetheless experience severe tumor-related and treatment-related cancer pain.
The pain is most likely to occur when these patients engage in everyday
activities, lowering daily life quality and task performance. Galena
Biopharma’s acquisition of this pain-reducing medical innovation and its revenue-generating
potential was a key factor for the company’s significant gains in the 2012 to
2013 near-year-end period.
Galena
Biopharma is backed by the leadership of the company’s CEO and President Mark
J. Ahn, PhD, an industry figure with over 20 years in the biopharmaceutical
industry. Bolstered by a savvy, professionally diverse management team with a
collective 80+ years of experience in the biopharmaceutical industry, the
company may well indeed be positioned for a strong 2014, as consistent with its
prior track record.
For
more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
